Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions;Les inhibiteurs de la phosphodiestérase en présence d'ischémie vasculaire: Un rapport de cas et une analyse de leur utilisation en cas de maladies ischémiques

Canadian Journal of Plastic Surgery

Volumn 18, Issue 1, 2010, Pages

  Ng, Wendy K Y ^a,b   Rosenblatt, Yishai ^a,b   Brock, Gerald B ^b,c,d   O'Gorman, David B ^a,b,d,e   Gan, Bing Siang ^a,b,d,e,f,g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c Division of Urology   (Canada)

^d Department of Surgery ^*  (Canada)

^e Division of Plastic Surgery   (Canada)

^f Departments of Physiology and Pharmacology   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Digital ischemia; Phosphodiesterase inhibitors (PDE inhibitors); Sildenafil; Skin flap survival

Indexed keywords

EID: 77954418326     PISSN: 11952199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. McLafferty RB, Edwards JM, Taylor LM Jr, Porter JM. Diagnosis and long-term clinical outcome in patients diagnosed with hand ischemia. J Vasc Surg 1995;22:361-7; discussion 367-9.
2. Croom KF, Curran MP. Sildenafil: A review of its use in pulmonary arterial hypertension. Drugs 2008;68:383-97.
3. Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008;1216:68-77.
4. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43.
5. Ruch DS, Holden M, Smith BP, Smith TL, Koman LA. Periarterial sympathectomy in scleroderma patients: Intermediate-term follow-up. J Hand Surg Am 2002;27:258-64.
6. Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008;34:89-114;vii.
7. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: Outcomes and considerations. J Rheumatol 2005;32:642-8.
8. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003;30:1788-92.
9. Sharma R. Novel phosphodiesterase-5 inhibitors: Current indications and future directions. Indian J Med Sci 2007;61:667-79.
10. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100:309-27.
11. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007;19:139-48.
12. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: A review of patient-preference studies. BJU Int 2009;103:1212-7.
13. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
14. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: Expanding roles in cardiovascular regulation. Circ Res 2007;101:1084-95.
15. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
16. Senthilkumar A, Smith RD, Khitha J, et al. Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol 2007;27:1947-54.
17. Kapur V, Chien CV, Fuess JE, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008;9:187-95.
18. Heymann WR. Sildenafil for the treatment of Raynaud's phenomenon. J Am Acad Dermatol 2006;55:501-2.
19. Yung A, Reay N, Goodfield MD. Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis. Arch Dermatol 2005;141:831-3.
20. Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: Successful treatment with sildenafil. J Rheumatol 2005;32:2440-2.
21. Francis SH, Corbin JD. Sildenafil: Efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 2005;1:283-93.
22. Hayreh SS. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: Is there a cause and effect relationship? J Neuroophthalmol 2005;25:295-8.
23. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: A review of the evidence to date. Drug Saf 2009;32:1-18.
24. Kontaras K, Varnavas V, Kyriakides ZS. Does sildenafil cause myocardial infarction or sudden cardiac death? Am J Cardiovasc Drugs 2008;8:1-7.
25. Levien TL. Phosphodiesterase inhibitors in Raynaud's phenomenon. Ann Pharmacother 2006;40:1388-93.
26. Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 2005;30:451.
27. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387.
28. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005;69:178-9.
29. Kumana CR, Cheung GT, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004;63:1522-4.
30. Ulusoy MG, Uysal A, Kocer U, et al. Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue. Ann Plast Surg 2005;55:292-6.
31. Sarifakioglu N, Gokrem S, Ates L, Akbuga UB, Aslan G. The influence of sildenafil on random skin flap survival in rats: An experimental study. Br J Plast Surg 2004;57:769-72.
32. Tsai JW, Ayubi FS, Hart KL, et al. Evaluation of the effect of sildenafil and vascular endothelium growth factor combination treatment on skin flap survival in rats. Aesthetic Plast Surg 2008;32:624-31.
33. Hart K, Baur D, Hodam J, et al. Short- and long-term effects of sildenafil on skin flap survival in rats. Laryngoscop 2006;116:522-8.
34. Oh M, Chang H, Minn KW. The effects of tadalafil on axial-pattern skin flap survival in rats. Dermatol Surg 2008;34:626-30; discussion 630.